dc.contributor.author | Demirkan, Fatih | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.date.accessioned | 2020-09-28T08:11:07Z | |
dc.date.available | 2020-09-28T08:11:07Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Demirkan, F. ve Sevindik, Ö. G. (2020). Real-world data from the Turkish national chronic lymphocytic leukemia registry. Clinical Lymphoma, Myeloma & Leukemia içinde (S229-S229. ss.). | en_US |
dc.identifier.issn | 2152-2650 | |
dc.identifier.issn | 2152-2669 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/5873 | |
dc.description.abstract | Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were diagnosed with CLL and over 18 years of age were included in the study. Data were collected starting from January 2017 from 20 centers that were located in different geographic parts of Turkey. Results: A total of 652 patients were enrolled in the study. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | CIG Media Group | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Chronic Lymphocytic Leukemia | en_US |
dc.subject | CLL | en_US |
dc.subject | Real-World | en_US |
dc.subject | Data | en_US |
dc.subject | Turkey | en_US |
dc.title | Real-world data from the Turkish national chronic lymphocytic leukemia registry | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Clinical Lymphoma, Myeloma & Leukemia | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | Supplement: 1 | en_US |
dc.identifier.startpage | S229 | en_US |
dc.identifier.endpage | S229 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q3 | en_US |